Concerns? Fair enough, but with what we actually know of the process currently underway, little can be a foregone conclusion. Having Orbimed in the boardroom is, admittedly, less than ideal, but the again, Orbimed could have washed their hands of the issue weeks ago... but they didn't. Just suggesting that the jury's still out.
UNS Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held